Study to Determine the Optimal Biologic Dose of CC-401 in Subjects With High-Risk Myeloid Leukemia

NCT00126893 · clinicaltrials.gov ↗
PHASE1
Phase
TERMINATED
Status
36
Enrollment
INDUSTRY
Sponsor class

Conditions

Interventions

Sponsor

Celgene Corporation